The India peptide synthesis market size reached USD 30.86 Million in 2025 and is projected to grow to USD 52.48 Million by 2034, at a CAGR of 6.08% during the forecast period of 2026-2034. Driven by government support through the Production-Linked Incentive scheme, the expansion of CRDMO capabilities, and rising demand for complex peptide therapeutics like GLP-1 receptor agonists, the market reflects expanding opportunities and strengthening infrastructure. the report offers a comprehensive analysis of the industry, including India peptide synthesis market growth, share, and regional insights.

Sample Request Link: https://www.imarcgroup.com/india-peptide-synthesis-market/requestsample

MARKET TRENDS

Government support is a key trend shaping the India peptide synthesis market. The Production-Linked Incentive (PLI) scheme, part of a broader INR 15,000 crore program, offers performance-linked financial incentives targeting critical bulk drugs and APIs. By March 2025, 38 essential APIs have been domestically produced, covering approximately 67% of previously imported APIs. Complementary infrastructure developments like bulk drug parks and raised foreign direct investment limits further create a conducive environment for growth. These initiatives reduce barriers to entry and promote innovation in peptide synthesis technologies.

The rapid expansion of Contract Research, Development, and Manufacturing Organization (CRDMO) capabilities is progressing in India’s pharmaceutical sector. Leading firms are investing in advanced peptide research and manufacturing centers, incorporating automation, robotics, and high-throughput platforms. In 2025, Sai Life Sciences launched a dedicated Peptide Research Center in Hyderabad and broke ground on a 100,000-square-foot Process R&D Center. These investments support peptides’ appeal in oncology, metabolic, cardiovascular, and infectious diseases due to their specificity and reduced off-target effects.

MARKET GROWTH FACTORS

India’s government-led Production-Linked Incentive (PLI) scheme is a major growth driver, initially allocating INR 6,940 crore (USD 850 million) for key bulk drugs, including APIs and intermediates. By incentivizing incremental domestic sales over six years, the program tackles import dependence especially on China. By supporting infrastructure development and raising foreign investment limits, the scheme enables financial backing for capital-intensive setups, advanced equipment, and quality systems, accelerating peptide synthesis market growth, particularly for anti-diabetic and anti-obesity therapeutics.

Another primary growth factor is the rapid expansion of CRDMO and CDMO capabilities with cutting-edge peptide synthesis infrastructure. Investments made in 2025 by Sai Life Sciences—such as a Peptide Research Center in Hyderabad and a new CMC Process R&D Center—highlight this trend. These developments boost process efficiency, scalability, and capabilities in peptide synthesis, appealing to oncology, metabolic, cardiovascular, and infectious disease markets due to high specificity and safety profiles, enhancing India’s competitive position in global pharmaceutical manufacturing.

Discuss Your Needs with Our Analyst – Get Customized Report Now